As Device Center Director Gets The Hook, Spotlight Turns To CDER's Woodcock
Executive Summary
For the pharmaceutical industry, the resignation of Center for Devices and Radiological Health Director Dan Schultz probably should be weighed in the context of what it means for interactions with CDER and CBER
You may also be interested in...
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Jury verdict comes seven years after Momenta/Sandoz launched generic version of Lovenox; firms sought treble damages from Amphastar for willful infringement of manufacturing process patent.
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies
FDA approval of Momenta and Sandoz' generic version of Sanofi-Aventis' Lovenox (enoxaparin) suggests the agency is willing to find a way around requiring clinical efficacy and safety data for future biosimilar approvals